Related Experiment Video
Updated: Jun 16, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Race, stability of health insurance coverage, and prescription medication use
Karen P Winters1, Sharon B Wyatt, Todd G Nick
1School of Nursing, University of Mississippi Medical Center, Jackson, MS 39216, USA. kwinters@son.umsmed.edu
Objective:
To determine the effects of health insurance and race on prescription medication use and expense.
Methods:
An observational, non-experimental design was used. Multivariable regression analyses were conducted to evaluate the independent effects of health insurance status and race on prescription medication use and expense while controlling for sociodemographic, geographic, and health status characteristics. The sample consisted of 19,035 participants in the 1996 through 2003 Medical Expenditure Panel Survey.
Findings:
European Americans spent about $300 to $400 more and used three to four more prescriptions annually compared to other racial groups. Prescription medication expenses increased as time spent uninsured increased. Participants with part-year coverage filled four fewer prescriptions than those with full-year health insurance coverage. Participants with private coverage spent less on prescription medications compared to those with public and those with dual public and private coverage ($1,194 vs. $1,931 and $2,076, respectively; p < or = 0.001).
Conclusions:
Significant racial and health insurance status disparities in prescription medication use and expenses exist after controlling for sociodemographic, geographic, and health status characteristics.
Related Concept Videos
Regression Toward the Mean
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Dosing: Geriatric Patients
Drug Toxicity: Risk factors